The molecule is not new. What changed is that the FDA finally added it to the U.S. over the counter monograph, after a 20 year wait that left American formulations behind their European and Asian counterparts on UVA protection.
For roughly twenty years, American sunscreen formulations have been working with a constrained set of tools. The active ingredients approved by the U.S. Food and Drug Administration before this week dated, in most cases, to the late 1990s and early 2000s. Meanwhile, cosmetics chemists elsewhere had access to a generation of newer UV filters designed to better cover the longer UVA wavelengths that drive skin aging and contribute to melanoma risk.
That changed on Tuesday, June 9, 2026, when the FDA approved bemotrizinol as an active sunscreen ingredient for over-the-counter use in the United States. According to Gizmodo's report on the approval, bemotrizinol is the first new sunscreen active greenlit by the FDA in the U.S. in roughly two decades — the previous approvals of this kind date to the 2000s. The decision closes a transatlantic gap that has been a quiet irritant to dermatologists and a louder one to consumer advocates for years.
Bemotrizinol itself is not a new molecule. It has been used in sunscreens sold in Europe, Australia, and much of Asia for decades, with a safety record accumulated across those markets. The Environmental Working Group, a consumer advocacy organization that supports the use of bemotrizinol and maintains a widely used sunscreen guide, noted in a press release that "for decades, Americans have used outdated sunscreen tech while the rest of the world moved forward." What is new is its U.S. status: the FDA added it to the OTC sunscreen monograph, the regulatory pathway that lets ingredients deemed generally recognized as safe and effective reach store shelves without a separate premarket approval application for each product.
The application was filed by DSM Nutritional Products LLC, the nutritional and personal care ingredients arm of what is now dsm-firmenich, for use at concentrations up to 6%. The FDA first publicly signaled it was evaluating bemotrizinol in December 2025, according to Gizmodo's write-up.
Why this matters comes down to UVA. UVB is the shorter-wavelength ultraviolet light that causes sunburn, and it has been relatively well covered by older U.S. filters. UVA penetrates deeper into the skin, drives much of the photoaging consumers associate with wrinkles and sunspots, and plays a documented role in skin cancer risk. European formulations have historically combined filters that more evenly cover the UVA spectrum, including bemotrizinol. U.S. formulations have had fewer options, which is why American sunscreens often rely on avobenzone paired with stabilizers to extend UVA coverage, with mixed results, CNN reported, citing dermatology expertise.
"Better access to sunscreens with strong UVA protection is a win for consumers," said Alexa Friedman, a senior scientist at the Environmental Working Group, in a statement cited by Gizmodo. David Andrews, Ph.D., EWG's chief science officer, said in the group's press release: "This is a great day for American consumers and everyone who has fought to improve sunscreen options and close the UVA protection gap in U.S. sunscreens. For decades, Americans have used outdated sunscreen tech while the rest of the world moved forward. The approval of bemotrizinol will help change that. The FDA's go-ahead will finally bring more effective, safer sun protection to American store shelves. This is a win that has been a long time coming."
The approval was framed by the Department of Health and Human Services under the Trump administration as fulfilling a commitment in the Make America Healthy Again (MAHA) Strategy Report, the policy blueprint associated with Health Secretary Robert F. Kennedy Jr. "As promised in the Trump Administration's MAHA Strategy Report, HHS is advancing innovation by bringing a new sunscreen ingredient to the U.S. market for the first time in 20 years," Kennedy said in a statement. The MAHA framing sits on top of a regulatory process that began before the current administration: the FDA's December 2025 evaluation notice and the underlying DSM application predate the political frame the approval received this week. Treating the molecule as a partisan deliverable flattens a longer story about why the U.S. sunscreen monograph fell behind its international peers in the first place.
That story is partly about regulatory capacity. The FDA's over-the-counter drug review process has long been under-resourced, and the sunscreen monograph was caught in a backlog that effectively froze the active-ingredient list. It is also about safety standards. The FDA's threshold for sunscreen actives has been more conservative than the standards applied by European and Australian regulators, partly because the U.S. framework demands a higher evidentiary bar for ingredients absorbed through the skin at meaningful levels. The result has been a long waiting list of filters, including bemotrizinol, that the rest of the world had already cleared.
What the approval does and does not do is worth separating. It gives formulators a new UVA filter with a long track record abroad, available for use in U.S. products up to 6%. It does not, on its own, fix UVA protection across the U.S. market. Sunscreen performance depends on the full formulation: the concentration of each active, the stabilizer system, and how well the product is applied. Consumers should expect to see bemotrizinol appearing in higher-end and dermatology-focused U.S. sunscreens first, with broader retail rollout following as brands reformulate.
Three milestones are worth watching. Look for the FDA's formal Federal Register notice confirming the monograph amendment, which will lock in bemotrizinol's legal status for OTC use. Watch for the first U.S. products listing bemotrizinol on their labels, which will signal that reformulation pipelines are live. And watch for the next filter applications moving through the FDA's queue, because bemotrizinol is unlikely to be the last sunscreen active that the U.S. market has waited a generation to access.